Synergistic anticancer effects of camptothecin and sotorasib in KRAS-mutated pancreatic ductal adenocarcinoma

BackgroundSotorasib (AMG510) is a first-in-class irreversible, covalent, and selective KRAS G12C inhibitor. However, in patients, acquired clinical resistance was observed within 1 year of its FDA approval. Researchers are exploring combination and repurposing strategies to help overcome this resist...

Full description

Bibliographic Details

Published in:	Frontiers in Pharmacology
Main Authors:	Prasanna Srinivasan Ramalingam, Gayathri Chellasamy, Md Sadique Hussain, Gothandam Kodiveri Muthukaliannan, Tajamul Hussain, Salman Alrokayan, Kyusik Yun, Janaki Ramaiah Mekala, Sivakumar Arumugam
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2025-07-01
Subjects:	alkaloid camptothecin sotorasib KRAS mutation PDAC synergistic effect
Online Access:	https://www.frontiersin.org/articles/10.3389/fphar.2025.1635449/full